This study is looking at how Broad Spectrum Cannabidiol (bsCBD) might help young adults (ages 18-25) who use cannabis regularly and have symptoms of cannabis use disorder (CUD). You could be eligible if you use cannabis frequently, are not trying to quit, and meet certain criteria for CUD. The study aims to see if taking 400 mg of bsCBD daily, compared to a placebo (an inactive substance), can reduce the harms linked to cannabis use. Researchers will measure differences in cannabis use and levels of cannabis-related substances in your blood over 8 weeks to see if bsCBD has a positive effect. The current recruitment status is unclear.

Study design

This is an interventional study with 200 planned participants. Participants will be randomly assigned to receive either Broad Spectrum Cannabidiol (bsCBD) or a placebo.

What's involved

Participants will take medication by mouth with food in the morning and evening. Blood samples will be taken at baseline, 4 weeks, and 8 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints are measured at 8 weeks, indicating a follow-up period of at least 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.